Together, we’ll achieve more.

The highly targeted SureSeq Myeloid MRD Panel enables the detection of 13 key AML MRD-associated biomarkers to provide a more comprehensive picture of the current AML status of your samples. Key targets include very large, ultra-low frequency FLT3-ITDs (even up to 300 bp) that are traditionally challenging to detect. The streamlined, guideline-driven panel content expands on OGT customer’s MRD detection capabilities to deliver a better understanding of the current AML status, and ensures genomic insights are not missed.

Improving upon existing SureSeq technology, this latest SureSeq NGS panel unlocks more efficient and expansive genetic profiling for CLL samples. The figure (right) illustrates the panel's uniformity and high depth of coverage, allowing the confident detection of [A] a SF3B1 exon 15 hotspot variant Lys700Glu with 4.8% allele frequency and [B] a TP53 exon 4 frameshift deletion (TP53 c.124del) with frequency 38.9%.

The IGK Breakapart probe consists of a 183kb probe, labeled in red, covering a part of the distal IGK Variable region and a green probe, covering a 606kb region including the D2S2216 and D2S2510 markers which is telomeric to the Joining segments and the Constant segment of IGK. The IGL product consists of a 278kb probe, labeled in red, centromeric to the IGL Variable region and covering the MAPK1 gene, and a green probe, covering a 307kb region telomeric to the IGL Constant segment, including the BCR gene.